On July 10, 2012, India's Supreme Court will hear the challenge to the country's patent law by Novartis, a case with enormous ramifications for the production of low-cost generic medications.
India's Supreme Court will now begin hearing a challenge to the country's patent law by the Swiss pharmaceutical company Novartis on July 10, 2012.
The Novartis Supreme Court case is the final act in a legal battle that stretches back six years and has significant ramifications for India's future capacity to produce low-cost generic medicines for its people, and for patients across developing countries.
Given the possible implications for generic production and the availability of affordable medicines from India, Doctors Without Borders/Médecins Sans Frontières (MSF), along with other treatment providers, patient groups and affected communities, has appealed to Novartis to drop its case against the “pharmacy of the developing world”.
MSF launched a social media campaign calling for Novartis to stop its legal attacks against India which threaten access to medicines for its patients. To participate in the Stop Novartis campaign, visit msfaccess.org/STOPnovartis
